Damora Therapeutics (NASDAQ: DMRA) granted equity inducement awards to nine newly hired, non-executive employees on July 1, 2026. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), are non-qualified stock options for an aggregate 453,500 shares at a $26.01 exercise price.
The options have a 10-year term and vest 25% on the first anniversary of each employee’s start date, then in equal monthly installments over the following 36 months, under the 2022 Damora Therapeutics Inducement Plan and related award agreements.
Loading...
Loading translation...
Positive
Inducement grants cover 453,500 options for newly hired employees
10-year option term with structured four-year vesting schedule
Grants align with Nasdaq Listing Rule 5635(c)(4) requirements
Negative
Potential dilution from 453,500 new stock option grants
News Market Reaction – DMRA
+10.67%
13 alerts
+10.67%Session close to close
+7.6%Peak in 28 hr 26 min
$1.85BMarket Cap
0.7xRel. Volume
In the Jul 2 session, DMRA gained 10.67%, reflecting a significant positive market reaction.
Argus tracked a peak move of +7.6% during that session.
Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
The stock surged +10.7% in the session following this news. A strong positive reaction aligns with p...
Analysis
The stock surged +10.7% in the session following this news. A strong positive reaction aligns with prior favorable responses to significant corporate updates, while past routine inducement grants saw modest moves. With low short positioning, enthusiasm may hinge on confidence in retaining and motivating new hires.
Key Figures
New hires:9 employeesOption grant size:453,500 sharesOption exercise price:$26.01 per share+3 more
6 metrics
New hires9 employeesRecipients of July 1, 2026 inducement equity grants
Option grant size453,500 sharesAggregate non-qualified stock options in inducement grants
Option exercise price$26.01 per shareExercise price for inducement stock options granted July 1, 2026
Option term10 yearsDuration of non-qualified stock options under inducement grants
Cliff vesting portion25%Portion of options vesting on first anniversary of start date
Remainder vesting period36 monthsMonthly vesting period after first-year cliff for remaining options
Appointment of Jennifer Jarrett as CEO and addition of two directors to board.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
DMRA has typically moved in line with the tone of past news, with the CEO appointment drawing a notably strong positive reaction versus modest moves on routine inducement grants.
"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise pricefinancial
"with a 10-year term and an exercise price of $26.01 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement planregulatory
"subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common stock with a 10-year term and an exercise price of $26.01 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a non-qualified stock option award agreement.
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
What equity inducement grants did Damora Therapeutics (NASDAQ: DMRA) announce on July 1, 2026?
Damora Therapeutics announced non-qualified stock option inducement grants covering 453,500 shares to nine newly hired, non-executive employees. According to Damora, these options were granted on July 1, 2026 as material inducements to employment and approved by the Board’s independent Compensation Committee.
How many Damora Therapeutics (DMRA) shares are covered by the new inducement stock options?
The inducement stock options cover an aggregate of 453,500 shares of Damora common stock. According to Damora, all options were granted to nine newly hired, non-executive employees as part of their compensation packages under the company’s 2022 Inducement Plan.
What is the exercise price and term of the new Damora Therapeutics (DMRA) inducement options?
The inducement options have a 10-year term and an exercise price of $26.01 per share. According to Damora, these non-qualified stock options were granted under the 2022 Damora Therapeutics Inducement Plan and related non-qualified stock option award agreements.
How do Damora Therapeutics (DMRA) inducement grants vest for the nine new employees?
The inducement options vest 25% on the first anniversary of each employee’s start date. According to Damora, the remaining 75% vests in equal monthly installments over the following 36 months, creating a four-year vesting schedule tied to ongoing employment.
Under which plan were the Damora Therapeutics (DMRA) inducement stock options granted?
The inducement stock options were granted under the 2022 Damora Therapeutics Inducement Plan. According to Damora, the awards are also governed by the terms and conditions of a non-qualified stock option award agreement for each participating employee.
How does Nasdaq Listing Rule 5635(c)(4) relate to Damora Therapeutics (DMRA) inducement grants?
Damora states that the inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Damora, the rule allows equity awards as material inducements to employment without prior shareholder approval, when approved by an independent compensation committee.
